Cancer Cachexia clinical trials

Explore recruiting cancer cachexia clinical trials.

Recruiting cancer cachexia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Cancer Cachexia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

C3651003 A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY, SAFETY AND TOLERABILITY OF PONSEGROMAB IN PATIENTS WITH CANCER, CACHEXIA, AND ELEVATED CONCENTRATIONS OF GDF-15, FOLLOWED BY AN OPTIONAL OPEN-LABEL TREATMENT PERIOD (PROACC -1)

Bulgaria, Poland, Spain, Slovakia

Therapeutic exploratory (Phase II) EU CTIS Study details

C3651021: A PHASE 2b/3, RANDOMIZED, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY, SAFETY, AND TOLERABILITY OF PONSEGROMAB (PF-06946860) COMPARED WITH PLACEBO BOTH WITH BACKGROUND FIRST-LINE CHEMOTHERAPY IN ADULT PARTICIPANTS WITH CACHEXIA AND METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA

Slovakia, Italy, Belgium, Germany, Spain, France +2 more

Phase II and Phase III (Integrated) EU CTIS Study details

Adaptive, Phase 2/3, Randomized, Double-Blind Trial Investigating the Efficacy and Safety of Visugromab versus Placebo in Patients with Cancer-associated Cachexia

France, Czechia, Romania, Italy, Germany, Poland +5 more

Phase II and Phase III (Integrated) EU CTIS Study details

A Phase 2, Multicenter, Randomized, Double blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of NGM120 in Participants with Colorectal Cancer who have Cancer Cachexia

Czechia, Slovakia, Poland, Hungary, Bulgaria

Therapeutic exploratory (Phase II) EU CTIS Study details

Cancer Cachexia trials by city

Cancer Cachexia in Toronto Cancer Cachexia in Vancouver Cancer Cachexia in Montreal Cancer Cachexia in Calgary Cancer Cachexia in Edmonton Cancer Cachexia in Ottawa Cancer Cachexia in Winnipeg Cancer Cachexia in Quebec City Cancer Cachexia in Hamilton Cancer Cachexia in Kitchener Cancer Cachexia in London Cancer Cachexia in Halifax Cancer Cachexia in New York Cancer Cachexia in Los Angeles Cancer Cachexia in Chicago Cancer Cachexia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease